PuSH - Publikationsserver des Helmholtz Zentrums München

Sheng, X.* ; Nenseth, H.Z.* ; Qu, S.* ; Kuzu, O.F.* ; Frahnow, T. ; Simon, L. ; Greene, S.* ; Zeng, Q.* ; Fazli, L.* ; Rennie, P.S.* ; Mills, I.G.* ; Danielsen, H.* ; Theis, F.J. ; Patterson, J.B.* ; Jin, Y.* ; Saatcioglu, F.*

IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.

Nat. Commun. 10:323 (2019)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Activation of endoplasmic reticulum (ER) stress/the unfolded protein response (UPR) has been linked to cancer, but the molecular mechanisms are poorly understood and there is a paucity of reagents to translate this for cancer therapy. Here, we report that an IRE1 alpha RNase-specific inhibitor, MKC8866, strongly inhibits prostate cancer (PCa) tumor growth as monotherapy in multiple preclinical models in mice and shows synergistic antitumor effects with current PCa drugs. Interestingly, global transcriptomic analysis reveal that IRE1 alpha-XBP1s pathway activity is required for c-MYC signaling, one of the most highly activated oncogenic pathways in PCa. XBP1s is necessary for optimal c-MYC mRNA and protein expression, establishing, for the first time, a direct link between UPR and oncogene activation. In addition, an XBP1-specific gene expression signature is strongly associated with PCa prognosis. Our data establish IRE1 alpha-XBP1s signaling as a central pathway in PCa and indicate that its targeting may offer novel treatment strategies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
11.878
2.805
69
91
Tags
icb_biostatistics
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Unfolded Protein Response; Endoplasmic-reticulum Stress; Transcriptional Program; Androgen Receptor; Inhibition; Antitumor; Synergy; Drives
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 2041-1723
e-ISSN 2041-1723
Zeitschrift Nature Communications
Quellenangaben Band: 10, Heft: 1, Seiten: , Artikelnummer: 323 Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-503800-001
Scopus ID 85060515552
PubMed ID 30679434
Erfassungsdatum 2019-03-11